SCHEMBL3811269

SCHEMBL3811269

NC(=O)Cc1ccc(C(=O)N2C3CCC2CC(O)C3)cc1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
VNN1 O95497 1/20 0.45
CA2 P00918 1/20 0.41
KDM1A O60341 3/20 0.40
F2 P00734 2/20 0.39
PRSS1 P07477 2/20 0.39
PLG P00747 1/20 0.39
PRSS2 P07478 1/20 0.39
C1S P09871 1/20 0.39
PRSS3 P35030 1/20 0.39
ELOVL6 Q9H5J4 1/20 0.38
POLB P06746 1/20 0.38
ITGB3 P05106 1/20 0.36
ITGA2B P08514 1/20 0.36
HRH3 Q9Y5N1 1/20 0.35
TPSAB1 Q15661 1/20 0.35
TPSD1 Q9BZJ3 1/20 0.35
TPSG1 Q9NRR2 1/20 0.35
TRPV4 Q9HBA0 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3818102 0.87 HRH3 (0.42) CA2KDM1AF2PRSS1PLG
SCHEMBL3809718 0.79 VNN1 (0.49) VNN1KDM1AELOVL6POLBHRH3
SCHEMBL3809715 0.77 VNN1 (0.47) VNN1ELOVL6POLBHRH3TRPV4
SCHEMBL21162194 0.77 ELOVL6 (0.53) VNN1ELOVL6POLB
SCHEMBL21461944 0.74 VNN1 (0.43) VNN1KDM1AELOVL6POLBTRPV4
SCHEMBL3811405 0.74 HDAC6 (0.53) VNN1KDM1AELOVL6POLB
SCHEMBL3818145 0.74 VNN1 (0.40) VNN1ELOVL6POLBHRH3
SCHEMBL3456718 0.74 ALDH1A1 (0.44) VNN1ELOVL6POLB
SCHEMBL3829393 0.72 KDM1A (0.51) KDM1A
SCHEMBL3809057 0.72 HDAC1 (0.52) VNN1ELOVL6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090124598-A1 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES HIGH POINT PHARMACEUTICALS, LLC 2009-05-14 US claimed
EP-1948190-A2 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES TRANSTECH PHARMA (US) 2008-07-30 EP claimed
WO-2007051810-A2 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES TRANSTECH PHARMA (US) 2007-05-10 WO claimed
US-20090124598-A1 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES HIGH POINT PHARMACEUTICALS, LLC 2009-05-14 US disclosed
EP-1948190-A2 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES TRANSTECH PHARMA (US) 2008-07-30 EP disclosed
WO-2007051810-A2 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES TRANSTECH PHARMA (US) 2007-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124598-A1 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES HSD11B1, HSD11B2, HSD3B1 VNN1 2070/4885CA2 2011/4885KDM1A 1934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.